Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +1.49
Percentage change 1.37	%

Held by: IJH VTI IWM VB VXF VBK XMHQ IWO MDY IJK

Index	RUT	P/E	18.02	EPS (ttm)	6.11	Insider Own	2.53%	Shs Outstand	69.86M	Perf Week	4.26%
Market Cap	7.64B	Forward P/E	15.26	EPS next Y	7.21	Insider Trans	-4.46%	Shs Float	67.67M	Perf Month	8.72%
Income	428.48M	PEG	0.48	EPS next Q	1.56	Inst Own	99.25%	Short Float	6.28%	Perf Quarter	39.13%
Sales	1.44B	P/S	5.31	EPS this Y	6.98%	Inst Trans	-1.04%	Short Ratio	3.93	Perf Half Y	87.41%
Book/sh	14.51	P/B	7.58	EPS next Y	8.19%	ROA	26.15%	Short Interest	4.25M	Perf Year	77.61%
Cash/sh	10.90	P/C	10.09	EPS next 5Y	37.73%	ROE	54.26%	52W Range	50.20 - 126.89	Perf YTD	77.50%
Dividend Est.	-	P/FCF	19.35	EPS past 5Y	35.30%	ROI	26.06%	52W High	-13.27%	Beta	0.50
Dividend TTM	-	Quick Ratio	4.41	Sales past 5Y	36.54%	Gross Margin	64.49%	52W Low	119.22%	ATR (14)	4.10
Dividend Ex-Date	-	Current Ratio	4.68	EPS Y/Y TTM	1183.66%	Oper. Margin	31.47%	RSI (14)	61.73	Volatility	3.78% 4.03%
Employees	834	Debt/Eq	0.60	Sales Y/Y TTM	27.83%	Profit Margin	29.80%	Recom	1.17	Target Price	144.55
Option/Short	Yes / Yes	LT Debt/Eq	0.60	EPS Q/Q	-33.67%	Payout	0.00%	Rel Volume	1.07	Prev Close	108.56
Sales Surprise	3.13%	EPS Surprise	-1.62%	Sales Q/Q	22.50%	Earnings	Jul 31 BMO	Avg Volume	1.08M	Price	110.05
SMA20	4.47%	SMA50	3.70%	SMA200	43.12%	Trades		Volume	1,162,275	Change	1.37%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-24	Initiated	Redburn Atlantic	Buy	$175
Jul-10-24	Reiterated	JMP Securities	Mkt Outperform	$100 → $130
Dec-18-23	Downgrade	William Blair	Outperform → Mkt Perform
Dec-04-23	Initiated	TD Cowen	Outperform	$100
Sep-29-23	Initiated	William Blair	Outperform
Mar-08-23	Initiated	JMP Securities	Mkt Outperform	$120
Nov-30-22	Initiated	SVB Leerink	Outperform
Oct-13-22	Initiated	Mizuho	Buy	$105
May-09-22	Initiated	B. Riley Securities	Buy	$91
Apr-13-22	Initiated	Truist	Buy	$77
Feb-01-21	Initiated	SVB Leerink	Outperform	$24
Jun-29-20	Resumed	Jefferies	Buy	$29
Aug-16-19	Upgrade	CJS Securities	Market Perform → Market Outperform
Nov-02-17	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-08-16	Reiterated	RBC Capital Mkts	Outperform	$6 → $12
Sep-23-16	Resumed	Credit Suisse	Neutral
Feb-24-16	Reiterated	RBC Capital Mkts	Outperform	$9 → $6
Dec-11-15	Downgrade	Credit Suisse	Outperform → Neutral
Sep-30-15	Downgrade	Wells Fargo	Outperform → Market Perform
Jul-20-15	Initiated	Wells Fargo	Outperform

Show Previous Ratings

Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
Sep-15-24 08:45AM	Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 (GlobeNewswire)
Sep-05-24 08:30AM	Lantheus Appoints Julie Eastland as New Board Member (GlobeNewswire)
Aug-28-24 08:30AM	Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-20-24 08:30AM	Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 (GlobeNewswire)
07:01PM	Loading…
Aug-14-24 07:01PM	Insider Sale: Director Gerard Ber Sells 15,500 Shares of Lantheus Holdings Inc (LNTH) (GuruFocus.com)
Jul-31-24 07:13AM	Lantheus Holdings: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Lantheus Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-23-24 03:52AM	Nanotechnology in medicine: Who are the leading public companies? (Medical Device Network)
Jul-17-24 08:30AM	Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time (GlobeNewswire)
Jul-15-24 08:30AM	Lantheus Acquires NAV-4694, a Next-Generation Amyloid PET Imaging Agent for Alzheimer's Disease (GlobeNewswire)
Jul-10-24 04:11PM	Lantheus Stock Gets A Radioactive Surge On Medicare Proposal (Investor's Business Daily) +36.65% +16.42%
12:32PM	Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access (GlobeNewswire)
11:57AM	Why Lantheus Holdings Stock Is Skyrocketing Today (Motley Fool)
Jul-08-24 08:30AM	Lantheus Appoints Jamie Spaeth as Chief People Officer (GlobeNewswire)
06:48AM	Loading…
Jul-05-24 06:48AM	Is Lantheus Holdings Inc (NASDAQ:LNTH) the Best Jim Cramer Stock in 2024? (Insider Monkey)
Jul-04-24 07:47AM	Jim Cramer's Latest Stock Portfolio: Top 10 Recommendations (Insider Monkey)
Jun-27-24 07:05AM	Lantheus Acquires Global Rights to Life Molecular Imaging's Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers (GlobeNewswire)
Jun-24-24 09:50AM	Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term (Zacks)
Jun-20-24 08:41PM	Radiopharm Receives Strategic Investment for up to A$18 million (GlobeNewswire)
Jun-18-24 06:15PM	Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know (Zacks)
11:47AM	Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock? (Zacks)
Jun-10-24 06:15PM	Lantheus Holdings (LNTH) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Jun-03-24 08:30AM	Lantheus' AI-Enabled aPROMISE Now Available on Siemens Healthineers' syngo.via platform (GlobeNewswire)
May-31-24 12:00PM	Lantheus Holdings (LNTH) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
May-30-24 07:00PM	Director Heinz Maeusli Sells 18,373 Shares of Lantheus Holdings Inc (LNTH) (GuruFocus.com)
07:00PM	Insider Selling: Director Julie Mchugh Sells Shares of Lantheus Holdings Inc (LNTH) (GuruFocus.com)
11:55AM	Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now (Zacks)
May-28-24 09:40AM	Are Medical Stocks Lagging Lantheus (LNTH) This Year? (Zacks)
08:00AM	Lantheus to Present at the William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
12:45PM	Loading…
May-27-24 12:45PM	Is Lantheus Holdings (LNTH) a Solid Growth Stock? 3 Reasons to Think 'Yes' (Zacks)
09:55AM	Wall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 31.21%: Here's is How to Trade (Zacks)
May-24-24 09:45AM	Here's Why Lantheus Holdings (LNTH) is a Strong Growth Stock (Zacks)
May-20-24 09:00AM	Investors Heavily Search Lantheus Holdings, Inc. (LNTH): Here is What You Need to Know (Zacks)
May-15-24 04:30PM	Lantheus Announces Executive Appointments to Accelerate Innovation (GlobeNewswire)
07:00AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results (GlobeNewswire)
May-07-24 09:00AM	Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock (Zacks)
May-03-24 12:36PM	Lantheus Holdings, Inc. (NASDAQ:LNTH) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:24PM	Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up (Zacks)
09:31AM	Truist Raises Lantheus Holdings' PT to $94 From $82 After 'Solid' Q1 Beat, Keeps Buy Rating (MT Newswires)
03:04AM	Lantheus Holdings Inc (LNTH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ... (GuruFocus.com)
May-02-24 11:14AM	Lantheus Shares Rise After Reporting Higher Q1 Adjusted Earnings, Revenue; 2024 Guidance Raised (MT Newswires) +16.01%
10:30AM	Lantheus Holdings (LNTH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:14AM	Lantheus Holdings Inc (LNTH) Surpasses Q1 2024 Revenue and Earnings Estimates (GuruFocus.com)
08:35AM	Lantheus Holdings (LNTH) Q1 Earnings and Revenues Beat Estimates (Zacks)
07:32AM	Lantheus Holdings: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Lantheus Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 02:39PM	Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now (Zacks)
Apr-26-24 05:50PM	Here's Why Lantheus Holdings (LNTH) Gained But Lagged the Market Today (Zacks)
01:12PM	Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings (Zacks)
Apr-25-24 10:01AM	Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-24-24 06:00PM	Lantheus Holdings (LNTH) Outpaces Stock Market Gains: What You Should Know (Zacks)
09:00AM	Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Apr-23-24 09:45AM	Why Lantheus Holdings (LNTH) is a Top Growth Stock for the Long-Term (Zacks)
09:40AM	Is Lantheus (LNTH) Stock Undervalued Right Now? (Zacks)
Apr-19-24 12:10PM	Will Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Apr-18-24 08:00AM	Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time (GlobeNewswire)
Apr-15-24 06:00PM	Lantheus Holdings (LNTH) Stock Moves -0.89%: What You Should Know (Zacks)
09:50AM	Here's Why Lantheus Holdings (LNTH) is a Strong Momentum Stock (Zacks)
Apr-13-24 12:12PM	10 Most Undervalued Value Stocks To Buy Now (Insider Monkey)
Apr-11-24 09:00AM	Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Apr-10-24 02:18PM	Wall Street Favorites: 3 Russell 2000 Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
Apr-09-24 06:00PM	Lantheus Holdings (LNTH) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Apr-05-24 09:00AM	Is Trending Stock Lantheus Holdings, Inc. (LNTH) a Buy Now? (Zacks)
Apr-03-24 05:45PM	Lantheus Holdings (LNTH) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-28-24 10:04AM	Here's Why You Should Add Lantheus (LNTH) to Your Portfolio (Zacks)
07:30AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results (GlobeNewswire)
Mar-26-24 05:45PM	Lantheus Holdings (LNTH) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Mar-25-24 09:00AM	Is Most-Watched Stock Lantheus Holdings, Inc. (LNTH) Worth Betting on Now? (Zacks)
Mar-22-24 09:30AM	Lantheus (LNTH) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-20-24 05:45PM	Why Lantheus Holdings (LNTH) Outpaced the Stock Market Today (Zacks)
Mar-14-24 05:45PM	Lantheus Holdings (LNTH) Rises As Market Takes a Dip: Key Facts (Zacks)
09:50AM	Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term (Zacks)
Mar-13-24 04:30PM	The 7 Most Undervalued Mid-Cap Stocks to Buy in March 2024 (InvestorPlace)
Mar-12-24 09:00AM	Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Mar-11-24 07:01PM	Insider Sell: President Paul Blanchfield Sells Shares of Lantheus Holdings Inc (LNTH) (GuruFocus.com)
Mar-08-24 05:45PM	Lantheus Holdings (LNTH) Stock Moves -0.11%: What You Should Know (Zacks)
03:00AM	Director Sam Leno Sells Shares of Lantheus Holdings Inc (LNTH) (GuruFocus.com)
Mar-07-24 09:40AM	Is Lantheus (LNTH) a Great Value Stock Right Now? (Zacks)
Mar-06-24 09:55AM	Wall Street Analysts See a 44.13% Upside in Lantheus Holdings (LNTH): Can the Stock Really Move This High? (Zacks)
09:30AM	Wall Street Analysts See Lantheus Holdings (LNTH) as a Buy: Should You Invest? (Zacks)
Mar-05-24 10:15AM	Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use (Zacks)
08:30AM	Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
08:00AM	Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility (GlobeNewswire)
Mar-04-24 08:30AM	Lantheus Announces the FDA Approval of DEFINITY (Perflutren Lipid Microsphere) for Pediatric Patients (GlobeNewswire)
Feb-28-24 08:30AM	Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer (GlobeNewswire)
Feb-27-24 09:00AM	Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Feb-26-24 11:00AM	Here's Why You Should Add Lantheus (LNTH) to Your Portfolio (Zacks)
08:30AM	Lantheus to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-23-24 11:00AM	Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up (Zacks)
10:48AM	Lantheus Holdings, Inc. (NASDAQ:LNTH) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:30AM	Lantheus Holdings (LNTH) Recently Broke Out Above the 50-Day Moving Average (Zacks)
Feb-22-24 09:30AM	Lantheus Holdings (LNTH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +14.71%
08:30AM	Lantheus Holdings (LNTH) Q4 Earnings and Revenues Beat Estimates (Zacks)
08:12AM	Lantheus Holdings Inc Reports Robust Revenue Growth and Strong Earnings in Q4 and Full Year 2023 (GuruFocus.com)
07:33AM	Lantheus Holdings: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-19-24 09:55AM	Wall Street Analysts Think Lantheus Holdings (LNTH) Could Surge 58.6%: Read This Before Placing a Bet (Zacks)
09:30AM	Should You Invest in Lantheus Holdings (LNTH) Based on Bullish Wall Street Views? (Zacks)

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sabens Andrea	Officer	Sep 13 '24	Proposed Sale	104.10	341	35,498		Sep 13 01:29 PM
Thrall James H	Director	Aug 21 '24	Sale	98.52	1,000	98,520	34,207	Aug 23 04:30 PM
Thrall James H	Director	Aug 21 '24	Proposed Sale	98.52	1,000	98,520		Aug 21 09:51 AM
Niedzwiecki Daniel	See Remarks	Aug 14 '24	Sale	97.54	2,500	243,850	77,744	Aug 16 04:30 PM
Ber Gerard	Director	Aug 12 '24	Sale	96.48	15,500	1,495,396	21,221	Aug 14 04:56 PM
Niedzwiecki Daniel	Officer	Aug 14 '24	Proposed Sale	97.54	2,500	243,850		Aug 14 12:41 PM
Sabens Andrea	Officer	Aug 13 '24	Proposed Sale	97.83	341	33,360		Aug 13 10:59 AM
Blanchfield Paul	President	Aug 08 '24	Sale	96.39	2,000	192,780	98,980	Aug 12 05:09 PM
Gerard Ber	Director	Aug 12 '24	Proposed Sale	97.33	15,500	1,508,615		Aug 12 04:23 PM
Blanchfield Paul	Officer	Aug 08 '24	Proposed Sale	96.39	2,000	192,780		Aug 08 11:16 AM
Heino Mary Anne	Director	Aug 02 '24	Sale	95.50	10,481	1,000,900	454,923	Aug 06 04:30 PM
Heino Mary Anne	Officer	Aug 02 '24	Proposed Sale	95.42	10,481	1,000,115		Aug 02 04:21 PM
Sabens Andrea	Chief Accounting Officer	Jul 16 '24	Sale	124.96	1,796	224,423	60,420	Jul 17 04:30 PM
Sabens Andrea	Chief Accounting Officer	Jul 15 '24	Sale	123.15	341	41,994	62,216	Jul 17 04:30 PM
Pruden Gary J	Director	Jul 10 '24	Sale	95.04	12,530	1,190,851	11,978	Jul 12 04:30 PM
Sabens Andrea	Chief Accounting Officer	Jun 13 '24	Sale	79.77	341	27,202	62,557	Jun 17 04:30 PM
Blanchfield Paul	President	May 31 '24	Sale	80.82	1,179	95,287	101,498	Jun 04 04:30 PM
Niedzwiecki Daniel	See Remarks	May 30 '24	Sale	79.86	12,873	1,028,038	80,244	Jun 03 04:30 PM
Maeusli Heinz Christoph	Director	May 28 '24	Option Exercise	16.17	17,481	282,668	49,032	May 30 04:34 PM
Maeusli Heinz Christoph	Director	May 28 '24	Sale	79.19	18,373	1,454,989	23,340	May 30 04:34 PM
McHugh Julie	Director	May 28 '24	Sale	78.50	2,500	196,250	28,617	May 30 04:32 PM
Sabens Andrea	Chief Accounting Officer	May 13 '24	Sale	76.89	341	26,219	62,898	May 15 05:09 PM
Sabens Andrea	Chief Accounting Officer	Apr 15 '24	Sale	61.24	341	20,883	63,239	Apr 17 04:30 PM
Marshall Robert J. Jr.	CFO and Treasurer	Mar 15 '24	Sale	60.00	20,000	1,200,000	113,749	Mar 19 04:30 PM
Sabens Andrea	Chief Accounting Officer	Mar 13 '24	Sale	60.48	341	20,624	63,204	Mar 15 04:30 PM
Blanchfield Paul	President	Mar 07 '24	Sale	61.96	18,023	1,116,705	103,357	Mar 11 04:30 PM
Lantheus Alpha Therapy, LLC	10% Owner	Mar 06 '24	Buy	0.95	60,431,039	57,409,487	116,773,394	Mar 08 11:24 AM
LENO SAM R	Director	Mar 05 '24	Option Exercise	16.30	2,045	33,334	59,982	Mar 07 04:30 PM
LENO SAM R	Director	Mar 06 '24	Option Exercise	16.30	2,045	33,334	59,982	Mar 07 04:30 PM
LENO SAM R	Director	Mar 05 '24	Sale	64.62	2,045	132,148	57,937	Mar 07 04:30 PM
LENO SAM R	Director	Mar 06 '24	Sale	63.50	2,045	129,857	57,937	Mar 07 04:30 PM
LENO SAM R	Director	Mar 04 '24	Option Exercise	19.85	22,389	444,499	80,326	Mar 06 05:15 PM
LENO SAM R	Director	Mar 04 '24	Sale	65.42	22,389	1,464,749	57,937	Mar 06 05:15 PM
Heino Mary Anne	Director	Mar 04 '24	Sale	65.31	93,863	6,129,889	251,643	Mar 05 08:28 PM
Sabens Andrea	Chief Accounting Officer	Feb 13 '24	Sale	55.31	341	18,861	58,403	Feb 15 04:30 PM
Sabens Andrea	Chief Accounting Officer	Jan 16 '24	Sale	56.01	341	19,099	58,744	Jan 18 04:30 PM
Marshall Robert J. Jr.	CFO and Treasurer	Dec 15 '23	Sale	78.24	10,000	782,400	103,170	Dec 19 05:00 PM
Sabens Andrea	Chief Accounting Officer	Dec 13 '23	Sale	75.62	341	25,786	59,085	Dec 15 04:30 PM
Blanchfield Paul	President	Nov 16 '23	Sale	67.96	1,500	101,940	88,651	Nov 20 04:30 PM
Heino Mary Anne	CEO	Nov 13 '23	Sale	63.72	11,780	750,611	317,687	Nov 15 04:32 PM
Sabens Andrea	Chief Accounting Officer	Nov 13 '23	Sale	63.57	341	21,677	59,426	Nov 15 04:30 PM

Open in Screener

YMAB

Y-Mabs Therapeutics Inc

Sep 20 • 04:00PM ET

13.73

Dollar change -0.27
Percentage change -1.93	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

YMAB Y-Mabs Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO IBB VTWO SCHA VHT IWC DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.56	Insider Own	17.16%	Shs Outstand	43.67M	Perf Week	-0.07%
Market Cap	611.95M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	-3.93%	Shs Float	36.92M	Perf Month	-0.87%
Income	-24.61M	PEG	-	EPS next Q	-0.15	Inst Own	57.36%	Short Float	11.35%	Perf Quarter	14.42%
Sales	86.55M	P/S	7.07	EPS this Y	-25.67%	Inst Trans	-3.41%	Short Ratio	14.90	Perf Half Y	-18.95%
Book/sh	2.14	P/B	6.42	EPS next Y	16.73%	ROA	-17.81%	Short Interest	4.19M	Perf Year	164.55%
Cash/sh	1.75	P/C	7.86	EPS next 5Y	-	ROE	-24.61%	52W Range	4.69 - 20.90	Perf YTD	101.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.06%	ROI	-25.70%	52W High	-34.31%	Beta	0.70
Dividend TTM	-	Quick Ratio	2.72	Sales past 5Y	37.03%	Gross Margin	88.62%	52W Low	192.75%	ATR (14)	0.94
Dividend Ex-Date	-	Current Ratio	2.92	EPS Y/Y TTM	37.14%	Oper. Margin	-31.94%	RSI (14)	52.25	Volatility	8.08% 7.19%
Employees	100	Debt/Eq	0.01	Sales Y/Y TTM	1.84%	Profit Margin	-28.44%	Recom	1.80	Target Price	20.80
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-45.60%	Payout	-	Rel Volume	3.94	Prev Close	14.00
Sales Surprise	-0.96%	EPS Surprise	-68.95%	Sales Q/Q	9.86%	Earnings	Aug 12 BMO	Avg Volume	281.32K	Price	13.73
SMA20	-1.59%	SMA50	7.33%	SMA200	8.97%	Trades		Volume	1,109,812	Change	-1.93%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-24	Initiated	Cantor Fitzgerald	Overweight	$20
Jun-28-24	Initiated	Truist	Buy	$21
May-10-23	Upgrade	Wedbush	Neutral → Outperform	$5 → $13
Apr-03-23	Downgrade	Guggenheim	Buy → Neutral
Jan-27-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$4
Jan-05-23	Downgrade	Cowen	Outperform → Market Perform
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral	$23 → $5
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral
Oct-31-22	Downgrade	Wedbush	Outperform → Neutral	$6
Oct-31-22	Downgrade	JP Morgan	Neutral → Underweight	$16 → $7
Jul-06-22	Resumed	Canaccord Genuity	Buy	$35
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$27
Feb-03-22	Resumed	Guggenheim	Buy	$22
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight	$25
Nov-16-21	Downgrade	JP Morgan	Overweight → Neutral	$57 → $30
May-07-21	Upgrade	BofA Securities	Neutral → Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-22-21	Resumed	JP Morgan	Overweight	$57 → $52
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral	$56
Nov-09-20	Reiterated	H.C. Wainwright	Buy	$52 → $65

Show Previous Ratings

Sep-06-24 07:30AM	Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research (GlobeNewswire)
Sep-03-24 08:32AM	Y-mAbs to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-24 06:33PM	Why Y-mAbs Therapeutics Stock Got Mashed on Monday (Motley Fool) -11.24% +8.74%
07:40AM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire)
07:20AM	Loading…
Aug-09-24 07:20AM	Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners Top Holdings Now? (Insider Monkey)
Aug-07-24 07:05AM	Y-mAbs to Participate in Upcoming Investor Conferences in August (GlobeNewswire)
Aug-05-24 04:05PM	Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast (GlobeNewswire) -6.27%
Jul-01-24 04:05PM	Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer (GlobeNewswire)
Jun-07-24 07:05AM	Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting (GlobeNewswire)
Jun-05-24 07:05AM	Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer (GlobeNewswire) +5.91%
Jun-01-24 08:15AM	Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting (GlobeNewswire)
08:05AM	Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting (GlobeNewswire)
May-09-24 11:58AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.44%
03:04AM	Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
09:57PM	Loading…
May-08-24 09:57PM	Q1 2024 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -20.92%
May-07-24 09:55PM	YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:12PM	Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates (GuruFocus.com)
05:55PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire)
Apr-26-24 07:05AM	Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 (GlobeNewswire)
Apr-25-24 04:05PM	Y-mAbs to Present at 2024 ASCO Annual Meeting (GlobeNewswire)
Mar-28-24 09:55AM	Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet (Zacks)
Mar-20-24 07:37AM	YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Mar-14-24 09:05AM	Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer (GlobeNewswire) -5.30%
Mar-12-24 09:55AM	Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High? (Zacks)
Mar-05-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice (Zacks)
Mar-04-24 08:45AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript (Insider Monkey) -7.28%
07:30AM	Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors (GlobeNewswire)
Mar-01-24 09:42PM	Q4 2023 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +11.92%
05:25PM	Loading…
Feb-29-24 05:25PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:37PM	Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Feb-22-24 10:00AM	Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline (Zacks)
Feb-16-24 07:30AM	Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024 (GlobeNewswire)
Feb-13-24 04:10AM	Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Jan-02-24 04:05PM	Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 04:05PM	Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index (GlobeNewswire)
Dec-12-23 01:05AM	Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (GuruFocus.com)
Dec-03-23 03:04AM	Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (GuruFocus.com)
Nov-30-23 11:04PM	Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (YMAB) (GuruFocus.com)
Nov-15-23 01:14PM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
01:33AM	Q3 2023 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-23 05:31PM	Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth Amidst Operational Streamlining (GuruFocus.com) +9.84%
05:25PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Nov-08-23 12:00PM	All You Need to Know About Y-mAbs Therapeutics, Inc. (YMAB) Rating Upgrade to Strong Buy (Zacks)
Oct-31-23 07:05AM	Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023 (GlobeNewswire)
Oct-18-23 04:05PM	Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director (GlobeNewswire)
Oct-17-23 04:05PM	Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA (GlobeNewswire)
Oct-16-23 04:05PM	Y-mAbs Announces Publication in Cancers (GlobeNewswire)
Sep-21-23 04:05PM	Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology (GlobeNewswire)
Sep-06-23 04:05PM	Y-mAbs to Participate at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-23-23 09:55AM	Wall Street Analysts Think Y-mAbs Therapeutics, Inc. (YMAB) Could Surge 88.55%: Read This Before Placing a Bet (Zacks)
Aug-13-23 06:25AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 05:15PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.48% -9.90%
04:05PM	Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Aug-02-23 04:05PM	Y-mAbs to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-01-23 04:05PM	Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023 (GlobeNewswire)
Jul-26-23 12:35PM	Institutional owners may take dramatic actions as Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent 13% drop adds to one-year losses (Simply Wall St.)
Jun-02-23 03:15PM	Y-mAbs Therapeutics (NASDAQ:YMAB investor three-year losses grow to 81% as the stock sheds US$53m this past week (Simply Wall St.) +5.01%
May-26-23 09:00AM	Y-mAbs Announces Presentation of Naxitamab Data at ASCO (GlobeNewswire)
09:00AM	Y-mAbs Announces Presentation of GD2-SADA Study at ASCO (GlobeNewswire)
May-23-23 09:00AM	Y-mAbs DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil (GlobeNewswire)
May-18-23 06:39AM	Daily Vickers Top Buyers & Sellers for 05/18/2023 (Argus Research) +8.39%
May-13-23 08:18AM	New Forecasts: Here's What Analysts Think The Future Holds For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) (Simply Wall St.)
May-10-23 06:14AM	Y-mAbs Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.) +7.26%
02:52AM	Q1 2023 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:15PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +36.34%
04:01PM	Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance (GlobeNewswire)
May-01-23 10:01AM	Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-28-23 09:00AM	Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023 (GlobeNewswire) +5.46%
Apr-18-23 09:00AM	Y-mAbs Announces Presentation of Naxitamab data at AACR (GlobeNewswire)
Apr-17-23 10:57AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Surges 104% Yet Its Low P/S Is No Reason For Excitement (Simply Wall St.)
Apr-05-23 07:44PM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2022 Earnings Call Transcript (Insider Monkey)
09:55AM	Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade (Zacks)
09:00AM	Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA (GlobeNewswire)
Apr-04-23 05:12AM	Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains? (Zacks)
Mar-30-23 05:25PM	Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates (Zacks) +52.28%
04:01PM	Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments (GlobeNewswire)
02:42PM	Dow futures down 0.1%, Virgin Orbit tanks 41.2% after-hours (Investing.com)
Mar-21-23 04:01PM	Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023 (GlobeNewswire) -5.35%
Mar-15-23 10:22AM	Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Feb-20-23 10:00AM	Analysts Estimate Apellis Pharmaceuticals, Inc. (APLS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-16-23 10:01AM	Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks) -8.37%
07:57AM	With 51% ownership, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) boasts of strong institutional backing (Simply Wall St.)
Feb-02-23 09:00AM	Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab (GlobeNewswire)
Jan-05-23 10:34AM	Y-mAbs Therapeutics Plans To Deprioritize Omburtamab For Pediatric Cancer, Cuts One Third Of Workforce (Benzinga) -7.83%
Jan-04-23 04:01PM	Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA (GlobeNewswire) +6.24%
Jan-03-23 09:00AM	Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 09:00AM	Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe (GlobeNewswire)
Dec-16-22 04:01PM	The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe (GlobeNewswire) -8.80%
Dec-14-22 09:00AM	Y-mAbs Announces Pipeline Update (GlobeNewswire)
Dec-08-22 09:00AM	Y-mAbs DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China (GlobeNewswire)
Dec-07-22 09:19AM	Shareholders in Y-mAbs Therapeutics (NASDAQ:YMAB) are in the red if they invested three years ago (Simply Wall St.) +7.42%
Dec-06-22 09:00AM	Y-mAbs to Host Annual Research and Development Day in New York (GlobeNewswire)
Dec-01-22 05:34PM	Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application (GlobeNewswire) -5.78%
Nov-07-22 05:15PM	YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +16.12%
04:01PM	Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire)
Nov-02-22 04:01PM	Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022 (GlobeNewswire) -8.54%

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gad Thomas	CHIEF BUSINESS OFFICER	Sep 19 '24	Option Exercise	4.38	22,831	100,000	181,531	Sep 20 04:15 PM
Gad Thomas	CHIEF BUSINESS OFFICER	Sep 13 '24	Sale	13.47	65,000	875,550	97,681	Sep 17 08:05 PM
Gad Thomas	CHIEF BUSINESS OFFICER	Sep 16 '24	Sale	12.97	30,000	389,100	67,681	Sep 17 08:05 PM
Thomas Gad	Officer	Sep 13 '24	Proposed Sale	13.74	100,000	1,374,000		Sep 13 04:19 PM
Ber Gerard	Director	Sep 03 '24	Proposed Sale	13.83	13,950	192,928		Sep 03 05:00 PM
Lund-Hansen Torben	SVP & CHIEF TECHNICAL OFFICER	Aug 28 '24	Option Exercise	4.38	50,000	219,000	85,600	Aug 30 04:15 PM
Lund-Hansen Torben	SVP & CHIEF TECHNICAL OFFICER	Aug 28 '24	Sale	15.37	50,000	768,500	35,600	Aug 30 04:15 PM
Lund-Hansen Torben	Officer	Aug 28 '24	Proposed Sale	15.37	50,000	768,432		Aug 28 05:12 PM
Wilms Joris	SVP & CHIEF OPERATING OFFICER	Aug 26 '24	Sale	14.69	5,000	73,450	30,600	Aug 27 05:05 PM
Wilms Joris	Officer	Aug 26 '24	Proposed Sale	14.69	5,000	73,450		Aug 26 04:12 PM
Ber Gerard	Director	Jun 10 '24	Sale	12.00	722	8,664	1,608	Jun 11 07:54 PM
Gad Thomas	CHIEF BUSINESS OFFICER	Jun 10 '24	Sale	12.03	35,000	421,050	197,681	Jun 11 07:53 PM
Gad Thomas	CHIEF BUSINESS OFFICER	Jun 11 '24	Sale	12.00	35,000	420,000	162,681	Jun 11 07:53 PM
Kruse Bo	EVP, CFO, SECRY & TREAS.	May 31 '24	Option Exercise	2.00	31,371	62,742	242,248	May 31 09:36 PM
Kruse Bo	EVP, CFO, SECRY & TREAS.	May 30 '24	Option Exercise	2.00	28,629	57,258	239,506	May 31 09:36 PM
Kruse Bo	EVP, CFO, SECRY & TREAS.	May 31 '24	Sale	12.07	31,371	378,648	210,877	May 31 09:36 PM
Kruse Bo	EVP, CFO, SECRY & TREAS.	May 30 '24	Sale	12.03	28,629	344,407	210,877	May 31 09:36 PM
Gad Thomas	CHIEF BUSINESS OFFICER	May 21 '24	Sale	12.00	25,000	300,000	240,032	May 23 06:54 PM
Gad Thomas	CHIEF BUSINESS OFFICER	May 23 '24	Sale	13.00	7,351	95,563	232,681	May 23 06:54 PM
Rajah Vignesh	SVP & CHIEF MEDICAL OFFICER	Mar 05 '24	Sale	16.53	1,711	28,283	33,889	Mar 07 05:02 PM
Gad Thomas	CHIEF BUSINESS OFFICER	Mar 05 '24	Sale	16.44	3,900	64,116	158,700	Mar 07 05:01 PM
Smith Susan Laura	SVP & CHIEF COMMERCIAL OFFICER	Mar 05 '24	Sale	16.55	1,682	27,837	33,918	Mar 07 04:59 PM
Gad Thomas	Chief Business Officer	Dec 21 '23	Option Exercise	2.00	50,000	100,000	140,500	Dec 26 04:15 PM
Gad Thomas	Chief Business Officer	Dec 14 '23	Sale	6.83	50,000	341,500	315,032	Dec 15 07:40 PM
Gad Thomas	Chief Business Officer	Dec 15 '23	Sale	6.61	50,000	330,500	265,032	Dec 15 07:40 PM
Gad Thomas	Chief Business Officer	Dec 13 '23	Sale	6.58	50,000	329,000	365,032	Dec 15 07:40 PM
WG Biotech ApS	Director	Dec 11 '23	Buy	6.85	6,455	44,232	4,559,233	Dec 12 08:27 AM
Wedell-Wedellsborg Johan	Director	Dec 11 '23	Buy	6.85	6,455	44,232	4,559,233	Dec 12 08:26 AM
WG Biotech ApS	Director	Dec 11 '23	Buy	7.01	102,863	720,843	4,552,778	Dec 11 05:25 PM
WG Biotech ApS	Director	Dec 08 '23	Buy	6.99	18,503	129,379	4,449,915	Dec 11 05:25 PM
WG Biotech ApS	Director	Dec 07 '23	Buy	6.50	6,183	40,190	4,431,412	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 11 '23	Buy	7.01	102,863	720,843	4,552,778	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 08 '23	Buy	6.99	18,503	129,379	4,449,915	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 07 '23	Buy	6.50	6,183	40,190	4,431,412	Dec 11 05:25 PM
WG Biotech ApS	Director	Nov 29 '23	Buy	5.97	51,837	309,477	4,425,229	Dec 01 05:15 PM
Wedell-Wedellsborg Johan	Director	Nov 29 '23	Buy	5.97	51,837	309,477	4,425,229	Dec 01 05:14 PM
Wedell-Wedellsborg Johan	Director	Nov 27 '23	Buy	5.49	62,516	343,019	4,342,721	Nov 29 05:15 PM
Wedell-Wedellsborg Johan	Director	Nov 28 '23	Buy	5.81	30,671	178,275	4,373,392	Nov 29 05:15 PM
WG Biotech ApS	Director	Nov 27 '23	Buy	5.49	62,516	343,019	4,342,721	Nov 29 05:14 PM
WG Biotech ApS	Director	Nov 28 '23	Buy	5.81	30,671	178,275	4,373,392	Nov 29 05:14 PM
Gad Thomas	Chief Business Officer	Nov 21 '23	Sale	5.31	75,000	397,988	415,032	Nov 22 05:00 PM
Gad Thomas	Chief Business Officer	Nov 20 '23	Sale	5.30	75,000	397,395	490,032	Nov 22 05:00 PM

LNTH

Lantheus Holdings Inc

YMAB

Y-Mabs Therapeutics Inc

Upgrade your FINVIZ experience